ArticleFrontiers in genetics2020

A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1.

Nan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.